| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Cell Growth & Differentiation, Vol 7, Issue 12 1609-1615, Copyright © 1996 by American Association of Cancer Research
ARTICLES |
M Gorospe, S Shack, KZ Guyton, D Samid and NJ Holbrook
Laboratory of Cellular and Molecular Biology, Gerontology Research Center, National Institute on Aging, NIH, Baltimore, Maryland 21224, USA.
Phenylacetate (PA) and related aromatic fatty acids constitute a novel class of relatively nontoxic antineoplastic agents. These compounds induce tumor cytostasis and growth inhibition and differentiation of cancer cells, but little is known regarding the molecular events mediating these biological effects. Using human breast carcinoma MCF-7 cells as a model, we show here that PA-induced growth arrest is associated with enhanced expression of the cyclin-dependent kinase inhibitor p21Waf1/Cip1 and dephosphorylation of the retinoblastoma protein (pRB). The induction of p21WAF1/CIP1 mRNA by PA was independent of the cellular p53 status. To directly assess the contribution of p21Waf1/Cip1 to PA-mediated cytostasis, we compared the effects of PA in parental MCF-7 cells and cells expressing reduced levels of p21Waf1/Cip1 protein (clones AS.3 and AS.4), accomplished through constitutive expression of antisense p21Waf1/Cip1 transcripts. In contrast to parental cells, AS.3 and AS.4 cells did not show reduced pRB phosphorylation following PA treatment, indicating that p21Waf1/Cip1 induction by PA is required for dephosphorylation (inactivation) of pRB, a known mediator of cell cycle control. A prominent role for p21Waf1/Cip1 in mediating PA-induced growth arrest was further supported by the demonstration that embryonal fibroblasts derived from a p21WAF1/CIP1 knockout mouse (p21-/- mouse embryonal fibroblasts) did not growth arrest following PA treatment, whereas PA effectively induced p21WAF1/CIP1 mRNA and growth inhibition of the wild-type mouse embryonal fibroblasts. Taken together, our findings strongly support a role for p21Waf1/Cip1 in the PA-mediated inhibition of cell growth.
This article has been cited by other articles:
![]() |
S. R. Burzynski, R. A. Weaver, T. Janicki, B. Szymkowski, G. Jurida, M. Khan, and V. Dolgopolov Long-term Survival of High-Risk Pediatric Patients With Primitive Neuroectodermal Tumors Treated With Antineoplastons A10 and AS2-1 Integr Cancer Ther, June 1, 2005; 4(2): 168 - 177. [Abstract] [PDF] |
||||
![]() |
S. R. Burzynski The Present State of Antineoplaston Research (1) Integr Cancer Ther, March 1, 2004; 3(1): 47 - 58. [Abstract] [PDF] |
||||
![]() |
C. Kennedy, K. Byth, C. L. Clarke, and A. deFazio Cell Proliferation in the Normal Mouse Mammary Gland and Inhibition by Phenylbutyrate Mol. Cancer Ther., October 1, 2002; 1(12): 1025 - 1033. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Kim, M.-S. Kim, K.-B. Kim, K.-W. Kim, Y.-M. Hong, I.-K. Kim, H.-W. Lee, and Y.-K. Jung Sensitizing effects of cadmium on TNF-{alpha}- and TRAIL-mediated apoptosis of NIH3T3 cells with distinct expression patterns of p53 Carcinogenesis, September 1, 2002; 23(9): 1411 - 1417. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Gartel and A. L. Tyner The Role of the Cyclin-dependent Kinase Inhibitor p21 in Apoptosis Mol. Cancer Ther., June 1, 2002; 1(8): 639 - 649. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Shin, K. Y. Ahn, H. Kook, J. T. Koh, I. C. Kang, H. C. Lee, and K. K. Kim Overexpressed Human RAD50 Exhibits Cell Death in a p21WAF1/CIP1-dependent Manner: Its Potential Utility in Local Gene Therapy of Tumor Cell Growth Differ., May 1, 2001; 12(5): 243 - 254. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Dixon, K. B. Knopf, and W. D. Figg The Control of Prostate-Specific Antigen Expression and Gene Regulation by Pharmacological Agents Pharmacol. Rev., March 1, 2001; 53(1): 73 - 92. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Pili, M. P. Kruszewski, B. W. Hager, J. Lantz, and M. A. Carducci Combination of Phenylbutyrate and 13-cis Retinoic Acid Inhibits Prostate Tumor Growth and Angiogenesis Cancer Res., February 1, 2001; 61(4): 1477 - 1485. [Abstract] [Full Text] |
||||
![]() |
T. Davis, C. Kennedy, Y.-E. Chiew, C. L. Clarke, and A. deFazio Histone Deacetylase Inhibitors Decrease Proliferation and Modulate Cell Cycle Gene Expression in Normal Mammary Epithelial Cells Clin. Cancer Res., November 1, 2000; 6(11): 4334 - 4342. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-L. Chung, Y.-H. W. Lee, S.-H. Yen, and K.-H. Chi A Novel Approach for Nasopharyngeal Carcinoma Treatment Uses Phenylbutyrate as a Protein Kinase C Modulator: Implications for Radiosensitization and EBV-targeted Therapy Clin. Cancer Res., April 1, 2000; 6(4): 1452 - 1458. [Abstract] [Full Text] |
||||
![]() |
D. Samid, M. Wells, M. E. Greene, W. Shen, C. N. A. Palmer, and A. Thibault Peroxisome Proliferator-activated Receptor {{gamma}} as a Novel Target in Cancer Therapy: Binding and Activation by an Aromatic Fatty Acid with Clinical Antitumor Activity Clin. Cancer Res., March 1, 2000; 6(3): 933 - 941. [Abstract] [Full Text] |
||||
![]() |
T. E. Witzig, M. Timm, M. Stenson, P. A. Svingen, and S. H. Kaufmann Induction of Apoptosis in Malignant B Cells by Phenylbutyrate or Phenylacetate in Combination with Chemotherapeutic Agents Clin. Cancer Res., February 1, 2000; 6(2): 681 - 692. [Abstract] [Full Text] |
||||
![]() |
E. Kebebew, M. G. Wong, A. E. Siperstein, Q.-Y. Duh, and O. H. Clark Phenylacetate Inhibits Growth and Vascular Endothelial Growth Factor Secretion in Human Thyroid Carcinoma Cells and Modulates Their Differentiated Function J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2840 - 2847. [Abstract] [Full Text] |
||||
![]() |
S. M. Chang, J. G. Kuhn, H. I. Robins, S. C. Schold, A. M. Spence, M. S. Berger, M. P. Mehta, M. E. Bozik, I. Pollack, D. Schiff, et al. Phase II Study of Phenylacetate in Patients With Recurrent Malignant Glioma: A North American Brain Tumor Consortium Report J. Clin. Oncol., March 1, 1999; 17(3): 984 - 984. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |